Dynacure S.A. (DYCU)

Chart not available yet

Market Cap	314.81M
Revenue (ttm)	n/a
Net Income (ttm)	-18.57M
Shares Out	19.68M
EPS (ttm)	-0.94
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	n/a
Previous Close	n/a
Day's Range	n/a
52-Week Range	n/a
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings Date	n/a

About DYCU

Dynacure S.A. is a clinical-stage company focused on developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. We are initially focused on developing treatments for neuromuscular diseases, beginning with myotubular and centronuclear myopathies, or CNM, a group of devastating rare genetic disorders characterized by severe muscle weakness, or myopathy, with shortened life expectancy and significant morbidity. Our lead product candidate, DYN101, is an antisense ol...

• Industry: Pharmaceutical Preparations
• IPO Date: Withdrawn
• CEO: Stéphane van Rooijen, M.D, M.B.A.
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: DYCU

Full Company Profile

Financial Performance

Financial numbers in millions EURFinancial Statements

News

Dynacure S.A. IPO Registration Document (S-1)

Dynacure S.A. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC